Enrollment concluded early in PCS-499 clinical trial for NL treatment
Category: #health  By Pankaj Singh  Date: 2019-08-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

Enrollment concluded early in PCS-499 clinical trial for NL treatment

Clinical stage biopharmaceutical firm Processa Pharmaceuticals Inc today announced the last patient to be enrolled in the Necrobiosis Lipoidica (NL) clinical study for PCS-499.

The conclusion of enrollment signifies an important milestone in the development of PCS-499 and is a step ahead for Processa in creating a potential new treatment for patients ailing from NL.

Dr. Sian Bigora, Chief Development Officer of Processa spoke about this achievement, stating that the early enrollment completion is a step closer in providing relief to patients of the disfiguring, chronic disease which is untreatable at present. He expressed the company’s eagerness to getting top-line safety and efficacy data later in 2019 followed by a meeting with the FDA to decide the next stages in attaining product approval.

Dr. David Young, CEO of Processa Pharmaceuticals also commented on the accomplishment adding a note of thanks to the patients and their families as well as the clinical sites who were a part of the study.

According to a previous press release on July 15, a PCS-499 dose of 1.8g per day, which is 50% higher than the maximum tolerated pentoxifylline dosage, was observed to be tolerated well with no reports of adverse events. Additionally, there were several positive efficacy trends observed in the patients participating in this trial.

Necrobiosis Lipoidica is a chronic, disfiguring condition that affects the skin and the tissue underneath the skin, characteristically on the lower extremities. Women are found to be more commonly affected by this condition with ulceration occurring in nearly 30% of patients. More severe symptoms can include deep tissue infections or osteonecrosis, which can be a threat to the limb. NL affects almost 74,000 – 185,000 people across the US and over 500,000 individuals over the world.

Tissue degeneration in NL occurs due to several pathopsychological changes which makes the development of effective treatments challenging. The PCS-499 and its metabolites target numerous biological pathways contributing to NL-associated pathophysiology, which will make it an effective treatment solution for NL patients.

Source credit: https://www.nasdaq.com/press-release/processa-pharmaceuticals-announces-last-patient-enrolled-in-clinical-trial-to-evaluate-the-safety-20190826-00438



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

RADLogics obtains FDA's approval for AI-based chest X-Ray App
RADLogics obtains FDA's approval for AI-based chest X-Ray App
By Pankaj Singh

RADLogics Inc., a healthcare software company developing AI-powered solutions has reportedly received 510(k) clearance from the US FDA (Food and Drug Administration) for its latest AI-Powered chest X-ray pneumothorax a...

CDE of China NMPA clears I-Mab’s application for lemzoparlimab
CDE of China NMPA clears I-Mab’s application for lemzoparlimab
By Pankaj Singh

Clinical stage biopharmaceutical major, I-Mab, has reportedly announced that it has received the clearance of the Center for Drug Evaluation of the China National Medical Products Administration for its IND application...

Aoyuan Healthy to acquire 55% equity interest in Liantianmei
Aoyuan Healthy to acquire 55% equity interest in Liantianmei
By Pankaj Singh

Aoyuan Healthy Life Group Company Ltd., a renowned commercial property operation service and property management service provider based in China, has reportedly announced that Guangdong Xinyuerong Industrial Investment...